

## CLAIMS

*Sub A1*

1. A therapeutic or preventive agent for cerebrovascular disorders, said agent comprising HGF gene and/or VEGF gene as an active ingredient.
2. A therapeutic or preventive agent according to claim 1 wherein cerebrovascular disorders are cerebrovascular obstruction, cerebral infarction, cerebral thrombosis, cerebral embolism, stroke, cerebral bleeding, moyamoya disease, cerebrovascular dementia, Alzheimer's dementia, and sequelae of cerebral bleeding or cerebral infarction.
3. A therapeutic or preventive agent for reduced blood flow in the brain comprising HGF gene and/or VEGF gene as an active ingredient.
4. A promoting agent for angiogenesis in the brain comprising HGF gene and/or VEGF gene as an active ingredient.
5. A suppressing agent for neuronal death in the brain comprising HGF gene as an active ingredient.
6. The suppressing agent according to claim 5 wherein neuronal death in the brain is delayed neuronal death caused by cerebral ischemia.
7. A suppressing agent for apoptosis of nerve cells in the brain comprising HGF gene as an active ingredient.
8. The agent according to any one of claims 1-7 which comprises HGF gene and/or VEGF gene as an active

ingredient and which is to be used in combination with HGF protein and/or VEGF protein.

9. The agent according to claim 8 which comprises HGF gene as an active ingredient and which is to be used in combination with HGF protein.

10. The agent according to any one of claims 1-9 wherein HGF gene and/or VEGF gene are in the form of HVJ-liposome.

11. The agent according to any one of claims 1-10 to be administered into the subarachnoid space.

12. The method of producing the agent according to any one of claims 1-11 comprising blending HGF gene and/or VEGF gene with a pharmaceutically acceptable solvent.

13. A therapeutic or preventive method for cerebrovascular disorders comprising introducing HGF gene and/or VEGF gene into humans.

14. A therapeutic or preventive method for reduced blood flow comprising introducing HGF gene and/or VEGF gene into humans.

15. A method of promoting cerebral angiogenesis comprising introducing HGF gene and/or VEGF gene into humans.

16. A method of suppressing neuronal death in the brain comprising introducing HGF gene into humans.

17. A method of suppressing apoptosis of nerve cells in the brain comprising introducing HGF gene into humans.

18. The method according to any one of claims 13-17 comprising administering HGF gene and/or VEGF gene into the subarachnoid space in humans.

19. The method according to any one of claims 13-18 comprising administering HGF protein and/or VEGF protein together with the introduction of HGF gene and/or VEGF gene.

20. The method according to claim 19 comprising administering HGF protein together with the introduction of HGF gene.

21. Use of HGF gene and/or VEGF gene in the manufacture of a therapeutic or preventive agent for cerebrovascular disorders.

22. Use of HGF gene and/or VEGF gene in the manufacture of a therapeutic or preventive agent for reduced blood flow in the brain.

23. Use of HGF gene and/or VEGF gene in the manufacture of a promoting agent for angiogenesis in the brain.

24. Use of HGF gene in the manufacture of a suppressing agent for neuronal death in the brain.

25. Use of HGF gene in the manufacture of a suppressing agent for apoptosis of nerve cells in the brain.